{
    "nct_id": "NCT04524455",
    "official_title": "A Phase 1b Open-label Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Administration of Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (ALL)",
    "inclusion_criteria": "Inclusion Criteria\n\n* Age ≥ 18 years at enrollment.\n* Greater than or equal to 5% blasts in the bone marrow.\n* Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 2.\n* Negative pregnancy test in women of childbearing potential.\n\nExclusion Criteria\n\n* Cancer chemotherapy (radiotherapy, chemotherapy, antibody therapy, molecular targeted therapy) within 14 days prior to study Day 1.\n* Known hypersensitivity to blinatumomab or AMG 404 or to any component of the product formulation.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}